Sjögren's syndrome medical therapy

Jump to navigation Jump to search

Sjögren's syndrome Microchapters



Historical Perspective




Differentiating Sjögren's syndrome from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings


X Ray

Echocardiography and Ultrasound



Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sjögren's syndrome medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Sjögren's syndrome medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sjögren's syndrome medical therapy

CDC on Sjögren's syndrome medical therapy

Sjögren's syndrome medical therapy in the news

Blogs on Sjögren's syndrome medical therapy

Directions to Hospitals Treating Sjögren's syndrome

Risk calculators and risk factors for Sjögren's syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Farima Kahe M.D. [2]


Pharmacologic medical therapies for dry eyes, dry mouth, and other sicca symptom of Sjögren's syndrome are pilocarpine, cevimeline and artificial tears.

Medical Therapy


  1. Wu AJ (November 2008). "Optimizing dry mouth treatment for individuals with Sjögren's syndrome". Rheum. Dis. Clin. North Am. 34 (4): 1001–10, x. doi:10.1016/j.rdc.2008.08.013. PMID 18984418.
  2. Thanou-Stavraki A, James JA (April 2008). "Primary Sjogren's syndrome: current and prospective therapies". Semin. Arthritis Rheum. 37 (5): 273–92. doi:10.1016/j.semarthrit.2007.06.002. PMID 17714766.
  3. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG (May 2012). "Topical and systemic medications for the treatment of primary Sjögren's syndrome". Nat Rev Rheumatol. 8 (7): 399–411. doi:10.1038/nrrheum.2012.53. PMID 22549247.
  4. Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R (December 2011). "Interventions for the management of dry mouth: topical therapies". Cochrane Database Syst Rev (12): CD008934. doi:10.1002/14651858.CD008934.pub2. PMID 22161442.
  5. Nobeyama Y, Matsuzaki H, Nakagawa H (May 2014). "Annular erythema of Sjögren's syndrome treated successfully with low-dose cyclosporine". J. Dermatol. 41 (5): 463–4. doi:10.1111/1346-8138.12475. PMID 24801928.
  6. Yokota K, Shichinohe R, Hayasaka T (July 2005). "Topical tacrolimus in the treatment of annular erythema associated with Sjögren's syndrome". Clin. Exp. Dermatol. 30 (4): 450–1. doi:10.1111/j.1365-2230.2005.01803.x. PMID 15953102.
  7. Ramos-Casals M, Anaya JM, García-Carrasco M, Rosas J, Bové A, Claver G, Diaz LA, Herrero C, Font J (March 2004). "Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients". Medicine (Baltimore). 83 (2): 96–106. PMID 15028963.
  8. Shahin AA, El-Agha S, El-Azkalany GS (July 2014). "The effect of leflunomide on the eye dryness in secondary Sjögren's syndrome associated with rheumatoid arthritis and in rheumatoid arthritis patients". Clin. Rheumatol. 33 (7): 925–30. doi:10.1007/s10067-014-2548-8. PMID 24647977.